Results 81 to 90 of about 779,609 (165)
BACKGROUND: Limited data are available on long-term clinical outcomes regarding the switch from Remicade((R)) to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) patients.
Hoentjen, F. +15 more
core +1 more source
Abstract Objectives Adults with developmental and epileptic encephalopathies (DEEs) often enter adult neurology care without etiologic clarification because of incomplete transition from pediatric services, outdated investigations, and attenuation of childhood electro‐clinical features over time.
Giuseppe d’Orsi +10 more
wiley +1 more source
ABSTRACT Introduction Although lifestyle medicine plays a recognised role in rheumatic and musculoskeletal disease (RMD) management, understanding how it is experienced is essential for developing effective lifestyle interventions. This study aimed to explore experiences and the impact of lifestyle medicine in RMD care and identify key facilitators and
Megan Curran +7 more
wiley +1 more source
ABSTRACT Background Breast cancer and its treatments significantly affect women's daily functioning, including their ability to engage in work. While return to work has been widely studied as an outcome, less is known about how work participation is experienced and negotiated during active treatment, particularly in relation to patients’ functioning ...
Lucia Cadorin +4 more
wiley +1 more source
Background Comparing intravenous (IV) infliximab (IFX) with subcutaneous (SC) CT-P13 in inflammatory bowel disease (IBD) may inform clinical practice, particularly in patients in stable remission receiving maintenance therapy.
Fabio Salvatore Macaluso +10 more
doaj +1 more source
This review explores emerging 2D materials beyond graphene, including graphdiyne, phosphorene, borophene, siloxene, MBene, antimonene, and germanene for Li/Na–S batteries. It analyzes their roles as sulfur hosts, metallic anode protectors, separators, and electrolyte fillers, emphasizing polysulfide suppression, dendrite inhibition, and interfacial ...
Naveen Kumar T. R +7 more
wiley +1 more source
Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center [PDF]
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has been confirmed to be efficacious in inducing remission in inflammatory bowel diseases (IBD).
Nagy, Ferenc +32 more
core +2 more sources
ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS? [PDF]
Inflammatory bowel diseases (IBD) currently impose an immense social and economic burden on society in terms of both direct and indirect healthcare costs. Their incurable and progressive nature results in an unavoidable lifetime expense. The introduction
Fabio Vieira TEIXEIRA +2 more
doaj +1 more source
Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
Valeria Dipasquale, Ugo Cucinotta, Claudio Romano Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood “G.
Dipasquale V, Cucinotta U, Romano C
doaj
Clinical significance of vestibular assessment in otosclerosis [PDF]
Background: Otosclerosis, a 1ry osteodystrophy of the otic capsule, causes stapes fixation, progressive hearing loss, and may involve the vestibular system.
Ahmed Almeciry +2 more
doaj +1 more source

